Bioatla presented phase 2 clinical trial data at the iaslc 2023 north america conference on lung cancer and virtual kol event

Results from the phase 2 ba3011 clinical non-small cell lung cancer (nsclc) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints

BCAB Ratings Summary

BCAB Quant Ranking